The earnings call presented a positive outlook with significant revenue growth and successful clinical trial results for crofelemer, along with strategic regulatory advancements and expansion plans in the animal health market. However, these positive developments were offset by increased operational losses and net loss attributable to shareholders.

Company Guidance -

Q3 2025

During the earnings call for the second quarter of 2025, Jaguar Health reported a combined net revenue of approximately $3 million, marking a 35% increase compared to the first quarter of 2025 and a 10% increase compared to the second quarter of 2024. Mytesi prescription volume rose by 6.5% over the previous quarter. However, the company experienced a loss from operations of $8 million, an increase of $800,000 from the same period in 2024, and a net loss attributable to common shareholders of $10.4 million, up by $900,000. The non-GAAP recurring EBITDA showed a net loss reduction from $8.8 million in 2024 to $7.9 million in 2025. The financial guidance emphasized the importance of recent clinical and regulatory catalysts aiming to secure nondilutive funding and forge business development partnerships.

Significant Revenue Growth

The second quarter of 2025 saw a combined net revenue of approximately $3 million, representing a 35% increase compared to Q1 2025 and a 10% increase compared to Q2 2024.

Positive Clinical Trial Results for Crofelemer

Initial proof-of-concept results from a study in Abu Dhabi demonstrated that crofelemer reduced the required TPN and supplementary intravenous fluids in MVID and SBS patients by up to 27% and 12.5% respectively.

Regulatory Advancements for Crofelemer

Jaguar participated in an FDA Type C meeting, discussing two pathways for crofelemer's availability for metastatic breast cancer patients, highlighting an expanded access program and a pivotal treatment trial.

Expansion into Animal Health Market

Ongoing discussions with potential partners to expand Canalevia's approval from chemotherapy-induced diarrhea in dogs to general diarrhea in dogs globally.

Jaguar Animal Health (JAGX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JAGX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	- / -	-26.25	―	―	―
Aug 14, 2025	2025 (Q2)	-7.13 / -10.26	-101	89.84% (+90.74)	―
May 15, 2025	2025 (Q1)	- / -16.70	-90	81.44% (+73.30)	―
Mar 31, 2025	2024 (Q4)	-10.82 / -16.70	-90	81.44% (+73.30)	―
Nov 13, 2024	2024 (Q3)	-59.25 / -26.25	-570	95.39% (+543.75)	―
Aug 13, 2024	2024 (Q2)	-30.11 / -101.00	-630	83.97% (+529.00)	―
May 14, 2024	2024 (Q1)	- / -	-143.4	―	―
Apr 01, 2024	2023 (Q4)	-45.00 / -90.00	-3585	97.49% (+3495.00)	―
Nov 14, 2023	2023 (Q3)	-1845.00 / -570.00	-13500	95.78% (+12930.00)	―
Aug 14, 2023	2023 (Q2)	-2295.00 / -630.00	-13500	95.33% (+12870.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JAGX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$2.59	$2.07	-20.08%
May 15, 2025	$6.17	$5.50	-10.86%
Mar 31, 2025	$5.00	$4.76	-4.80%
Nov 13, 2024	$27.25	$24.69	-9.39%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Jaguar Animal Health (JAGX) report earnings?

Jaguar Animal Health (JAGX) is schdueled to report earning on Nov 12, 2025, TBA (Confirmed).

What is Jaguar Animal Health (JAGX) earnings time?

Jaguar Animal Health (JAGX) earnings time is at Nov 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is JAGX EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing